Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk defended its obesity drug CagriSema despite disappointing trial data. The company remains optimistic about its efficacy compared to Wegovy. Upcoming trials aim to harness its weight-loss ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk recently reported data from a phase 1b/2a clinical trial for the subcutaneous ... Second, the medicine everyone ...

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...

referring to the CagriSema data. “Was it a tolerability issue that stopped people from taking the highest dose, or was there something else?” Analysts aren’t expecting the earnings ...

“At the annual results next week, it would be really valuable to understand more on this,” said Paul Middleton, a global equities fund manager at Mirabaud Asset Management, referring to the CagriSema ...

While the initial market reaction to Novo’s more enhanced CagriSema weight loss treatment was negative, we believe this is a more potent formulation that can better compete with Lilly’s suite.

which it announced it would start after late-stage trial data in December disappointed the market. That trial will study the long-term efficacy of CagriSema and was already planned as part of the ...